These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30346230)

  • 1. We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - No.
    Hellwig K
    Mult Scler; 2019 Feb; 25(2):189-190. PubMed ID: 30346230
    [No Abstract]   [Full Text] [Related]  

  • 2. We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.
    Alvarez E; Mowry EM
    Mult Scler; 2019 Feb; 25(2):187-188. PubMed ID: 30346221
    [No Abstract]   [Full Text] [Related]  

  • 3. We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Commentary.
    Bove R
    Mult Scler; 2019 Feb; 25(2):190-192. PubMed ID: 30346219
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple sclerosis disease-modifying therapy and pregnancy.
    Miller AE
    Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
    [No Abstract]   [Full Text] [Related]  

  • 5. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cases of pregnancy in patients with aggressive multiple sclerosis treated with natalizumab].
    Yakushina TI; Belova YA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):94-97. PubMed ID: 31156247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal outcome of pregnancy with ongoing treatment with natalizumab.
    Fagius J; Burman J
    Acta Neurol Scand; 2014 Jun; 129(6):e27-9. PubMed ID: 24527849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psycho-neuro-endocrino-immunologic issues in multiple sclerosis: a critical review of clinical and therapeutic implications.
    Anagnostouli M; Markoglou N; Chrousos G
    Hormones (Athens); 2020 Dec; 19(4):485-496. PubMed ID: 32488815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pregnancy and immunomodulatory therapy in multiple sclerosis patients].
    Hoffmann LA; Kümpfel T; Heer I; Hohlfeld R
    Nervenarzt; 2006 Jun; 77(6):663-4, 666-8, 670. PubMed ID: 16468069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell depletion and pregnancy: Review and applications for MS treatment.
    Shah S; Eckstein C
    Mult Scler Relat Disord; 2019 Aug; 33():153-157. PubMed ID: 31202154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient awareness about family planning represents a major knowledge gap in multiple sclerosis.
    Rasmussen PV; Magyari M; Moberg JY; Bøgelund M; Jensen UFA; Madsen KG
    Mult Scler Relat Disord; 2018 Aug; 24():129-134. PubMed ID: 30005355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.
    Fernández O; Delvecchio M; Edan G; Fredrikson S; Giovannoni G; Hartung HP; Havrdova E; Kappos L; Pozzilli C; Soerensen PS; Tackenberg B; Vermersch P; Comi G
    Eur J Neurol; 2018 May; 25(5):739-746. PubMed ID: 29356206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.
    Amato MP; Portaccio E
    CNS Drugs; 2015 Mar; 29(3):207-20. PubMed ID: 25773609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How safe is natalizumab during pregnancy?
    Duquette P; Prat A
    Mult Scler; 2015 Feb; 21(2):121-2. PubMed ID: 25392323
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
    Fragoso YD; Boggild M; Macias-Islas MA; Carra A; Schaerer KD; Aguayo A; de Almeida SM; Alvarenga MP; Alvarenga RM; Alves-Leon SV; Arruda WO; Brooks JB; Comini-Frota ER; Ferreira ML; Finkelsztejn A; Finkelsztejn JM; de Freitas LD; Gallina AS; da Gama PD; Georgetto S; Giacomo MC; Gomes S; Gonçalves MV; Grzesiuk AK; Kaimen-Maciel DR; Lopes J; Lourenco GA; Malfetano FR; Morales NM; Morales Rde R; Oliveira CL; Onaha P; Patroclo C; Ribeiro SB; Ribeiro TA; Salminen HJ; Santoro P; Seefeld M; Soares PV; Tarulla A; Vasconcelos CC
    Clin Neurol Neurosurg; 2013 Feb; 115(2):154-9. PubMed ID: 22633835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of pregnancy-related issues in patients with multiple sclerosis.
    Pozzilli C; Pugliatti M;
    Eur J Neurol; 2015 Oct; 22 Suppl 2():34-9. PubMed ID: 26374512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The need for a disease-specific prospective pregnancy registry for multiple sclerosis (MS).
    Alwan S; Chambers CD; Armenti VT; Sadovnick AD
    Mult Scler Relat Disord; 2015 Jan; 4(1):6-17. PubMed ID: 25787048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Thiel S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):801-9. PubMed ID: 26920382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.